nodes	percent_of_prediction	percent_of_DWPC	metapath
Levobupivacaine—CYP1A2—chronic obstructive pulmonary disease	0.552	1	CbGaD
Levobupivacaine—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0629	0.257	CbGbCtD
Levobupivacaine—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0511	0.209	CbGbCtD
Levobupivacaine—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0345	0.141	CbGbCtD
Levobupivacaine—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.033	0.135	CbGbCtD
Levobupivacaine—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0294	0.12	CbGbCtD
Levobupivacaine—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0172	0.0705	CbGbCtD
Levobupivacaine—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0163	0.0666	CbGbCtD
Levobupivacaine—Lidocaine—EGFR—chronic obstructive pulmonary disease	0.00101	0.228	CrCbGaD
Levobupivacaine—Bupivacaine—CYP1A2—chronic obstructive pulmonary disease	0.000953	0.215	CrCbGaD
Levobupivacaine—Ropivacaine—CYP1A2—chronic obstructive pulmonary disease	0.000768	0.173	CrCbGaD
Levobupivacaine—Tocainide—CYP1A2—chronic obstructive pulmonary disease	0.000722	0.163	CrCbGaD
Levobupivacaine—Lidocaine—CYP1A2—chronic obstructive pulmonary disease	0.000558	0.126	CrCbGaD
Levobupivacaine—CYP1A2—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.000442	0.0957	CbGpPWpGaD
Levobupivacaine—Tocainide—ALB—chronic obstructive pulmonary disease	0.000417	0.0942	CrCbGaD
Levobupivacaine—CYP3A4—Lidocaine metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000385	0.0835	CbGpPWpGaD
Levobupivacaine—CYP3A4—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.000341	0.0738	CbGpPWpGaD
Levobupivacaine—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—chronic obstructive pulmonary disease	0.000279	0.0604	CbGpPWpGaD
Levobupivacaine—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000263	0.00135	CcSEcCtD
Levobupivacaine—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000261	0.00134	CcSEcCtD
Levobupivacaine—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.00026	0.00133	CcSEcCtD
Levobupivacaine—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000259	0.00133	CcSEcCtD
Levobupivacaine—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000259	0.00133	CcSEcCtD
Levobupivacaine—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000257	0.00132	CcSEcCtD
Levobupivacaine—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000256	0.00131	CcSEcCtD
Levobupivacaine—Cough—Formoterol—chronic obstructive pulmonary disease	0.000256	0.00131	CcSEcCtD
Levobupivacaine—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000256	0.00131	CcSEcCtD
Levobupivacaine—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000255	0.00131	CcSEcCtD
Levobupivacaine—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000254	0.0013	CcSEcCtD
Levobupivacaine—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000254	0.0013	CcSEcCtD
Levobupivacaine—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000253	0.0013	CcSEcCtD
Levobupivacaine—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000253	0.0013	CcSEcCtD
Levobupivacaine—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000253	0.0013	CcSEcCtD
Levobupivacaine—Cardiac arrest—Prednisolone—chronic obstructive pulmonary disease	0.000251	0.00129	CcSEcCtD
Levobupivacaine—Cough—Montelukast—chronic obstructive pulmonary disease	0.000251	0.00129	CcSEcCtD
Levobupivacaine—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.00025	0.00128	CcSEcCtD
Levobupivacaine—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.00025	0.00128	CcSEcCtD
Levobupivacaine—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.00025	0.00128	CcSEcCtD
Levobupivacaine—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000249	0.00128	CcSEcCtD
Levobupivacaine—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000249	0.00128	CcSEcCtD
Levobupivacaine—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000249	0.00128	CcSEcCtD
Levobupivacaine—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000249	0.00128	CcSEcCtD
Levobupivacaine—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000249	0.00128	CcSEcCtD
Levobupivacaine—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000248	0.00127	CcSEcCtD
Levobupivacaine—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000248	0.00127	CcSEcCtD
Levobupivacaine—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000248	0.00127	CcSEcCtD
Levobupivacaine—Neuropathy—Prednisone—chronic obstructive pulmonary disease	0.000248	0.00127	CcSEcCtD
Levobupivacaine—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000245	0.00126	CcSEcCtD
Levobupivacaine—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000245	0.00125	CcSEcCtD
Levobupivacaine—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000244	0.00125	CcSEcCtD
Levobupivacaine—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000243	0.00125	CcSEcCtD
Levobupivacaine—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000243	0.00125	CcSEcCtD
Levobupivacaine—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000243	0.00124	CcSEcCtD
Levobupivacaine—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000242	0.00124	CcSEcCtD
Levobupivacaine—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000239	0.00123	CcSEcCtD
Levobupivacaine—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000239	0.00123	CcSEcCtD
Levobupivacaine—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000239	0.00123	CcSEcCtD
Levobupivacaine—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000239	0.00123	CcSEcCtD
Levobupivacaine—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000239	0.00123	CcSEcCtD
Levobupivacaine—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000238	0.00122	CcSEcCtD
Levobupivacaine—Infection—Formoterol—chronic obstructive pulmonary disease	0.000238	0.00122	CcSEcCtD
Levobupivacaine—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000236	0.00121	CcSEcCtD
Levobupivacaine—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000236	0.00121	CcSEcCtD
Levobupivacaine—Pulmonary oedema—Prednisone—chronic obstructive pulmonary disease	0.000235	0.00121	CcSEcCtD
Levobupivacaine—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000235	0.00121	CcSEcCtD
Levobupivacaine—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000235	0.0012	CcSEcCtD
Levobupivacaine—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000235	0.0012	CcSEcCtD
Levobupivacaine—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000235	0.0012	CcSEcCtD
Levobupivacaine—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000235	0.0012	CcSEcCtD
Levobupivacaine—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000235	0.0012	CcSEcCtD
Levobupivacaine—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000234	0.0012	CcSEcCtD
Levobupivacaine—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000234	0.0012	CcSEcCtD
Levobupivacaine—Infection—Montelukast—chronic obstructive pulmonary disease	0.000233	0.00119	CcSEcCtD
Levobupivacaine—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.000233	0.00119	CcSEcCtD
Levobupivacaine—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000233	0.00119	CcSEcCtD
Levobupivacaine—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000233	0.00119	CcSEcCtD
Levobupivacaine—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000232	0.00119	CcSEcCtD
Levobupivacaine—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.00023	0.00118	CcSEcCtD
Levobupivacaine—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.00023	0.00118	CcSEcCtD
Levobupivacaine—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000228	0.00117	CcSEcCtD
Levobupivacaine—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.000227	0.00116	CcSEcCtD
Levobupivacaine—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000226	0.00116	CcSEcCtD
Levobupivacaine—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000226	0.00116	CcSEcCtD
Levobupivacaine—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000225	0.00115	CcSEcCtD
Levobupivacaine—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000224	0.00115	CcSEcCtD
Levobupivacaine—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000224	0.00115	CcSEcCtD
Levobupivacaine—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000223	0.00114	CcSEcCtD
Levobupivacaine—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000222	0.00114	CcSEcCtD
Levobupivacaine—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	0.000222	0.00114	CcSEcCtD
Levobupivacaine—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000222	0.00114	CcSEcCtD
Levobupivacaine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000221	0.00113	CcSEcCtD
Levobupivacaine—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.00022	0.00113	CcSEcCtD
Levobupivacaine—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000219	0.00112	CcSEcCtD
Levobupivacaine—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000219	0.00112	CcSEcCtD
Levobupivacaine—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000218	0.00112	CcSEcCtD
Levobupivacaine—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000218	0.00112	CcSEcCtD
Levobupivacaine—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000217	0.00111	CcSEcCtD
Levobupivacaine—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000217	0.00111	CcSEcCtD
Levobupivacaine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000215	0.0011	CcSEcCtD
Levobupivacaine—Vascular purpura—Prednisone—chronic obstructive pulmonary disease	0.000214	0.0011	CcSEcCtD
Levobupivacaine—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000214	0.0011	CcSEcCtD
Levobupivacaine—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000213	0.00109	CcSEcCtD
Levobupivacaine—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000213	0.00109	CcSEcCtD
Levobupivacaine—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000213	0.00109	CcSEcCtD
Levobupivacaine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000213	0.00109	CcSEcCtD
Levobupivacaine—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000212	0.00109	CcSEcCtD
Levobupivacaine—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000211	0.00108	CcSEcCtD
Levobupivacaine—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000211	0.00108	CcSEcCtD
Levobupivacaine—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000211	0.00108	CcSEcCtD
Levobupivacaine—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000211	0.00108	CcSEcCtD
Levobupivacaine—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.00021	0.00108	CcSEcCtD
Levobupivacaine—Injury—Prednisone—chronic obstructive pulmonary disease	0.000209	0.00107	CcSEcCtD
Levobupivacaine—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000209	0.00107	CcSEcCtD
Levobupivacaine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000208	0.00107	CcSEcCtD
Levobupivacaine—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000207	0.00106	CcSEcCtD
Levobupivacaine—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000207	0.00106	CcSEcCtD
Levobupivacaine—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000206	0.00106	CcSEcCtD
Levobupivacaine—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000206	0.00106	CcSEcCtD
Levobupivacaine—Pain—Formoterol—chronic obstructive pulmonary disease	0.000205	0.00105	CcSEcCtD
Levobupivacaine—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000205	0.00105	CcSEcCtD
Levobupivacaine—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000205	0.00105	CcSEcCtD
Levobupivacaine—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000205	0.00105	CcSEcCtD
Levobupivacaine—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000204	0.00105	CcSEcCtD
Levobupivacaine—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000203	0.00104	CcSEcCtD
Levobupivacaine—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000202	0.00104	CcSEcCtD
Levobupivacaine—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000202	0.00103	CcSEcCtD
Levobupivacaine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000201	0.00103	CcSEcCtD
Levobupivacaine—Pain—Montelukast—chronic obstructive pulmonary disease	0.000201	0.00103	CcSEcCtD
Levobupivacaine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.0002	0.00103	CcSEcCtD
Levobupivacaine—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000199	0.00102	CcSEcCtD
Levobupivacaine—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000199	0.00102	CcSEcCtD
Levobupivacaine—Purpura—Prednisone—chronic obstructive pulmonary disease	0.000199	0.00102	CcSEcCtD
Levobupivacaine—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000197	0.00101	CcSEcCtD
Levobupivacaine—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000197	0.00101	CcSEcCtD
Levobupivacaine—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000197	0.00101	CcSEcCtD
Levobupivacaine—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000197	0.00101	CcSEcCtD
Levobupivacaine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000196	0.00101	CcSEcCtD
Levobupivacaine—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000196	0.001	CcSEcCtD
Levobupivacaine—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000196	0.001	CcSEcCtD
Levobupivacaine—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.000196	0.001	CcSEcCtD
Levobupivacaine—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000195	0.001	CcSEcCtD
Levobupivacaine—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000193	0.000991	CcSEcCtD
Levobupivacaine—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000193	0.000991	CcSEcCtD
Levobupivacaine—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000192	0.000983	CcSEcCtD
Levobupivacaine—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.000192	0.000983	CcSEcCtD
Levobupivacaine—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.00019	0.000975	CcSEcCtD
Levobupivacaine—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.00019	0.000975	CcSEcCtD
Levobupivacaine—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000189	0.000971	CcSEcCtD
Levobupivacaine—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000189	0.000971	CcSEcCtD
Levobupivacaine—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000189	0.000971	CcSEcCtD
Levobupivacaine—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000189	0.000971	CcSEcCtD
Levobupivacaine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000189	0.000967	CcSEcCtD
Levobupivacaine—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000187	0.000958	CcSEcCtD
Levobupivacaine—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000186	0.000955	CcSEcCtD
Levobupivacaine—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000186	0.000955	CcSEcCtD
Levobupivacaine—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000186	0.000953	CcSEcCtD
Levobupivacaine—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000186	0.000953	CcSEcCtD
Levobupivacaine—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000185	0.000951	CcSEcCtD
Levobupivacaine—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000185	0.000951	CcSEcCtD
Levobupivacaine—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000185	0.000948	CcSEcCtD
Levobupivacaine—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	0.000182	0.000935	CcSEcCtD
Levobupivacaine—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.00018	0.000921	CcSEcCtD
Levobupivacaine—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000179	0.000916	CcSEcCtD
Levobupivacaine—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000179	0.000916	CcSEcCtD
Levobupivacaine—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000176	0.000905	CcSEcCtD
Levobupivacaine—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000176	0.000905	CcSEcCtD
Levobupivacaine—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000176	0.000904	CcSEcCtD
Levobupivacaine—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000173	0.000886	CcSEcCtD
Levobupivacaine—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000172	0.000881	CcSEcCtD
Levobupivacaine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000172	0.000881	CcSEcCtD
Levobupivacaine—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000169	0.000869	CcSEcCtD
Levobupivacaine—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000169	0.000869	CcSEcCtD
Levobupivacaine—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000169	0.000867	CcSEcCtD
Levobupivacaine—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000169	0.000867	CcSEcCtD
Levobupivacaine—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000168	0.000863	CcSEcCtD
Levobupivacaine—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000167	0.000855	CcSEcCtD
Levobupivacaine—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000167	0.000854	CcSEcCtD
Levobupivacaine—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000166	0.000851	CcSEcCtD
Levobupivacaine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000164	0.00084	CcSEcCtD
Levobupivacaine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000164	0.00084	CcSEcCtD
Levobupivacaine—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000163	0.000836	CcSEcCtD
Levobupivacaine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000162	0.000832	CcSEcCtD
Levobupivacaine—Sweating increased—Prednisone—chronic obstructive pulmonary disease	0.000161	0.000828	CcSEcCtD
Levobupivacaine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.00016	0.000823	CcSEcCtD
Levobupivacaine—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.00016	0.00082	CcSEcCtD
Levobupivacaine—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.000159	0.000815	CcSEcCtD
Levobupivacaine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000158	0.000812	CcSEcCtD
Levobupivacaine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000158	0.000812	CcSEcCtD
Levobupivacaine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000155	0.000795	CcSEcCtD
Levobupivacaine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000155	0.000793	CcSEcCtD
Levobupivacaine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000152	0.000781	CcSEcCtD
Levobupivacaine—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000152	0.000781	CcSEcCtD
Levobupivacaine—Headache—Arformoterol—chronic obstructive pulmonary disease	0.00015	0.000769	CcSEcCtD
Levobupivacaine—Headache—Formoterol—chronic obstructive pulmonary disease	0.00015	0.000769	CcSEcCtD
Levobupivacaine—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.00015	0.000768	CcSEcCtD
Levobupivacaine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.00015	0.000767	CcSEcCtD
Levobupivacaine—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000149	0.000765	CcSEcCtD
Levobupivacaine—Headache—Montelukast—chronic obstructive pulmonary disease	0.000147	0.000753	CcSEcCtD
Levobupivacaine—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000145	0.000744	CcSEcCtD
Levobupivacaine—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000145	0.000743	CcSEcCtD
Levobupivacaine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000144	0.000737	CcSEcCtD
Levobupivacaine—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000142	0.000731	CcSEcCtD
Levobupivacaine—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000142	0.000729	CcSEcCtD
Levobupivacaine—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000142	0.000729	CcSEcCtD
Levobupivacaine—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000142	0.000726	CcSEcCtD
Levobupivacaine—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000141	0.0307	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.000141	0.0304	CbGpPWpGaD
Levobupivacaine—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.00014	0.000716	CcSEcCtD
Levobupivacaine—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000139	0.000714	CcSEcCtD
Levobupivacaine—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000138	0.000706	CcSEcCtD
Levobupivacaine—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000137	0.000703	CcSEcCtD
Levobupivacaine—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000135	0.000692	CcSEcCtD
Levobupivacaine—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000134	0.000689	CcSEcCtD
Levobupivacaine—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.00013	0.000665	CcSEcCtD
Levobupivacaine—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.00013	0.000665	CcSEcCtD
Levobupivacaine—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000128	0.000654	CcSEcCtD
Levobupivacaine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000127	0.000649	CcSEcCtD
Levobupivacaine—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000125	0.000643	CcSEcCtD
Levobupivacaine—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000123	0.000631	CcSEcCtD
Levobupivacaine—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.00012	0.0259	CbGpPWpGaD
Levobupivacaine—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000118	0.000608	CcSEcCtD
Levobupivacaine—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000117	0.000601	CcSEcCtD
Levobupivacaine—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000116	0.000597	CcSEcCtD
Levobupivacaine—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000116	0.000596	CcSEcCtD
Levobupivacaine—Erythema—Prednisone—chronic obstructive pulmonary disease	0.000115	0.000592	CcSEcCtD
Levobupivacaine—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000115	0.000592	CcSEcCtD
Levobupivacaine—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000111	0.000569	CcSEcCtD
Levobupivacaine—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.000109	0.0236	CbGpPWpGaD
Levobupivacaine—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000109	0.000558	CcSEcCtD
Levobupivacaine—CYP3A4—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.000108	0.0235	CbGpPWpGaD
Levobupivacaine—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000107	0.000548	CcSEcCtD
Levobupivacaine—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000107	0.000547	CcSEcCtD
Levobupivacaine—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000544	CcSEcCtD
Levobupivacaine—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000541	CcSEcCtD
Levobupivacaine—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000104	0.000531	CcSEcCtD
Levobupivacaine—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000103	0.000528	CcSEcCtD
Levobupivacaine—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000101	0.00052	CcSEcCtD
Levobupivacaine—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.0001	0.000513	CcSEcCtD
Levobupivacaine—Hypertension—Prednisone—chronic obstructive pulmonary disease	9.97e-05	0.000511	CcSEcCtD
Levobupivacaine—Arthralgia—Prednisone—chronic obstructive pulmonary disease	9.83e-05	0.000504	CcSEcCtD
Levobupivacaine—Anxiety—Prednisone—chronic obstructive pulmonary disease	9.8e-05	0.000502	CcSEcCtD
Levobupivacaine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	9.76e-05	0.000501	CcSEcCtD
Levobupivacaine—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	9.55e-05	0.00049	CcSEcCtD
Levobupivacaine—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	9.42e-05	0.000483	CcSEcCtD
Levobupivacaine—Oedema—Prednisone—chronic obstructive pulmonary disease	9.42e-05	0.000483	CcSEcCtD
Levobupivacaine—Infection—Prednisone—chronic obstructive pulmonary disease	9.36e-05	0.00048	CcSEcCtD
Levobupivacaine—Shock—Prednisone—chronic obstructive pulmonary disease	9.27e-05	0.000475	CcSEcCtD
Levobupivacaine—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	9.24e-05	0.000474	CcSEcCtD
Levobupivacaine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	9.2e-05	0.000472	CcSEcCtD
Levobupivacaine—Skin disorder—Prednisone—chronic obstructive pulmonary disease	9.15e-05	0.000469	CcSEcCtD
Levobupivacaine—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	9.11e-05	0.000467	CcSEcCtD
Levobupivacaine—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	8.59e-05	0.00044	CcSEcCtD
Levobupivacaine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	8.58e-05	0.00044	CcSEcCtD
Levobupivacaine—Insomnia—Prednisone—chronic obstructive pulmonary disease	8.52e-05	0.000437	CcSEcCtD
Levobupivacaine—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	8.46e-05	0.000434	CcSEcCtD
Levobupivacaine—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—chronic obstructive pulmonary disease	8.41e-05	0.0182	CbGpPWpGaD
Levobupivacaine—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	8.29e-05	0.000425	CcSEcCtD
Levobupivacaine—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	8.19e-05	0.00042	CcSEcCtD
Levobupivacaine—Headache—Prednisolone—chronic obstructive pulmonary disease	8.12e-05	0.000417	CcSEcCtD
Levobupivacaine—CYP1A2—Estrogen Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	8.12e-05	0.0176	CbGpPWpGaD
Levobupivacaine—Constipation—Prednisone—chronic obstructive pulmonary disease	8.06e-05	0.000413	CcSEcCtD
Levobupivacaine—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	7.77e-05	0.000398	CcSEcCtD
Levobupivacaine—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	7.71e-05	0.000395	CcSEcCtD
Levobupivacaine—Nausea—Prednisolone—chronic obstructive pulmonary disease	7.7e-05	0.000395	CcSEcCtD
Levobupivacaine—Urticaria—Prednisone—chronic obstructive pulmonary disease	7.49e-05	0.000384	CcSEcCtD
Levobupivacaine—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	7.45e-05	0.000382	CcSEcCtD
Levobupivacaine—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	7.45e-05	0.000382	CcSEcCtD
Levobupivacaine—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	7.3e-05	0.0158	CbGpPWpGaD
Levobupivacaine—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	6.94e-05	0.000356	CcSEcCtD
Levobupivacaine—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	6.88e-05	0.0149	CbGpPWpGaD
Levobupivacaine—Asthenia—Prednisone—chronic obstructive pulmonary disease	6.76e-05	0.000347	CcSEcCtD
Levobupivacaine—Pruritus—Prednisone—chronic obstructive pulmonary disease	6.67e-05	0.000342	CcSEcCtD
Levobupivacaine—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	6.65e-05	0.0144	CbGpPWpGaD
Levobupivacaine—CYP1A2—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	6.6e-05	0.0143	CbGpPWpGaD
Levobupivacaine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	6.45e-05	0.000331	CcSEcCtD
Levobupivacaine—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	6.37e-05	0.0138	CbGpPWpGaD
Levobupivacaine—CYP1A2—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	6.26e-05	0.0136	CbGpPWpGaD
Levobupivacaine—Dizziness—Prednisone—chronic obstructive pulmonary disease	6.23e-05	0.000319	CcSEcCtD
Levobupivacaine—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	6.11e-05	0.0132	CbGpPWpGaD
Levobupivacaine—Vomiting—Prednisone—chronic obstructive pulmonary disease	5.99e-05	0.000307	CcSEcCtD
Levobupivacaine—Headache—Prednisone—chronic obstructive pulmonary disease	5.9e-05	0.000303	CcSEcCtD
Levobupivacaine—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	5.88e-05	0.0127	CbGpPWpGaD
Levobupivacaine—CYP1A2—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	5.75e-05	0.0125	CbGpPWpGaD
Levobupivacaine—Nausea—Prednisone—chronic obstructive pulmonary disease	5.6e-05	0.000287	CcSEcCtD
Levobupivacaine—CYP1A2—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	5.53e-05	0.012	CbGpPWpGaD
Levobupivacaine—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	5.31e-05	0.0115	CbGpPWpGaD
Levobupivacaine—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	5.09e-05	0.011	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—GCLC—chronic obstructive pulmonary disease	4.84e-05	0.0105	CbGpPWpGaD
Levobupivacaine—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	4.83e-05	0.0105	CbGpPWpGaD
Levobupivacaine—CYP1A2—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	4.56e-05	0.00988	CbGpPWpGaD
Levobupivacaine—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	4.44e-05	0.00962	CbGpPWpGaD
Levobupivacaine—CYP1A2—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	4.27e-05	0.00926	CbGpPWpGaD
Levobupivacaine—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	4.27e-05	0.00925	CbGpPWpGaD
Levobupivacaine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	4e-05	0.00866	CbGpPWpGaD
Levobupivacaine—SCN4A—L1CAM interactions—EGFR—chronic obstructive pulmonary disease	3.87e-05	0.00838	CbGpPWpGaD
Levobupivacaine—SCN10A—L1CAM interactions—EGFR—chronic obstructive pulmonary disease	3.73e-05	0.00808	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—ADIPOQ—chronic obstructive pulmonary disease	3.45e-05	0.00749	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	3.36e-05	0.00729	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—ADIPOQ—chronic obstructive pulmonary disease	3.33e-05	0.00722	CbGpPWpGaD
Levobupivacaine—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	3.14e-05	0.0068	CbGpPWpGaD
Levobupivacaine—CYP1A2—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	2.95e-05	0.0064	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	2.95e-05	0.0064	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—chronic obstructive pulmonary disease	2.95e-05	0.0064	CbGpPWpGaD
Levobupivacaine—CYP1A2—Phase II conjugation—GSTT1—chronic obstructive pulmonary disease	2.91e-05	0.00631	CbGpPWpGaD
Levobupivacaine—CYP1A2—Phase II conjugation—GCLC—chronic obstructive pulmonary disease	2.88e-05	0.00624	CbGpPWpGaD
Levobupivacaine—CYP1A2—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	2.76e-05	0.00599	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	2.59e-05	0.00562	CbGpPWpGaD
Levobupivacaine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	2.54e-05	0.0055	CbGpPWpGaD
Levobupivacaine—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	2.5e-05	0.00542	CbGpPWpGaD
Levobupivacaine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	2.39e-05	0.00518	CbGpPWpGaD
Levobupivacaine—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	2.36e-05	0.00511	CbGpPWpGaD
Levobupivacaine—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	2.28e-05	0.00494	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—LEP—chronic obstructive pulmonary disease	2.15e-05	0.00465	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—LEP—chronic obstructive pulmonary disease	2.07e-05	0.00448	CbGpPWpGaD
Levobupivacaine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	2.06e-05	0.00446	CbGpPWpGaD
Levobupivacaine—CYP1A2—Phase II conjugation—GSTP1—chronic obstructive pulmonary disease	2.02e-05	0.00437	CbGpPWpGaD
Levobupivacaine—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	1.94e-05	0.0042	CbGpPWpGaD
Levobupivacaine—CYP1A2—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	1.85e-05	0.00402	CbGpPWpGaD
Levobupivacaine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	1.84e-05	0.00399	CbGpPWpGaD
Levobupivacaine—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	1.82e-05	0.00394	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—MMP9—chronic obstructive pulmonary disease	1.81e-05	0.00392	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—MMP9—chronic obstructive pulmonary disease	1.74e-05	0.00378	CbGpPWpGaD
Levobupivacaine—CYP1A2—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	1.7e-05	0.00369	CbGpPWpGaD
Levobupivacaine—CYP1A2—Biological oxidations—GCLC—chronic obstructive pulmonary disease	1.68e-05	0.00365	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	1.63e-05	0.00354	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—VEGFA—chronic obstructive pulmonary disease	1.62e-05	0.00352	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—VEGFA—chronic obstructive pulmonary disease	1.57e-05	0.00339	CbGpPWpGaD
Levobupivacaine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	1.49e-05	0.00324	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—EGFR—chronic obstructive pulmonary disease	1.46e-05	0.00317	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—EGFR—chronic obstructive pulmonary disease	1.41e-05	0.00305	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	1.38e-05	0.003	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	1.31e-05	0.00285	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	1.3e-05	0.00282	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—MMP9—chronic obstructive pulmonary disease	1.29e-05	0.0028	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	1.27e-05	0.00275	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	1.25e-05	0.0027	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	1.25e-05	0.0027	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—MMP9—chronic obstructive pulmonary disease	1.24e-05	0.0027	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	1.2e-05	0.00259	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	1.19e-05	0.00257	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	1.19e-05	0.00257	CbGpPWpGaD
Levobupivacaine—CYP1A2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	1.18e-05	0.00256	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	1.16e-05	0.00252	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	1.16e-05	0.00251	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—IL6—chronic obstructive pulmonary disease	1.12e-05	0.00243	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	1.12e-05	0.00242	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	1.09e-05	0.00237	CbGpPWpGaD
Levobupivacaine—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	1.08e-05	0.00235	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—IL6—chronic obstructive pulmonary disease	1.08e-05	0.00235	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	1.08e-05	0.00233	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	1.07e-05	0.00232	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	1.06e-05	0.0023	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—EGFR—chronic obstructive pulmonary disease	1.04e-05	0.00226	CbGpPWpGaD
Levobupivacaine—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	1.03e-05	0.00223	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	1.03e-05	0.00222	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	1.01e-05	0.0022	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—EGFR—chronic obstructive pulmonary disease	1.01e-05	0.00218	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—TNF—chronic obstructive pulmonary disease	9.93e-06	0.00215	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—TNF—chronic obstructive pulmonary disease	9.57e-06	0.00207	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	9.11e-06	0.00197	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	8.99e-06	0.00195	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	8.37e-06	0.00181	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	8.27e-06	0.00179	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	8.26e-06	0.00179	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—IL6—chronic obstructive pulmonary disease	8.01e-06	0.00174	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	7.94e-06	0.00172	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	7.83e-06	0.0017	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—IL6—chronic obstructive pulmonary disease	7.72e-06	0.00167	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	6.39e-06	0.00138	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	5.9e-06	0.00128	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	5.48e-06	0.00119	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	5.33e-06	0.00116	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	4.96e-06	0.00107	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.23e-06	0.000917	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	4.12e-06	0.000892	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	3.95e-06	0.000856	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.83e-06	0.000829	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.91e-06	0.000631	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	2.88e-06	0.000624	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	2.68e-06	0.000582	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	2.63e-06	0.000569	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.25e-06	0.000487	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	2.22e-06	0.000481	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	2.03e-06	0.000439	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.02e-06	0.000437	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.99e-06	0.000431	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.87e-06	0.000405	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.86e-06	0.000402	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.76e-06	0.000381	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.56e-06	0.000338	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.54e-06	0.000333	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.43e-06	0.00031	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.36e-06	0.000294	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	1.2e-06	0.000259	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	1.14e-06	0.000248	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	9.23e-07	0.0002	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	8.83e-07	0.000191	CbGpPWpGaD
